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ABSTRACT
Objectives: The overall objective of this study was to estimate the costs
and outcomes associated with treatment with valsartan for post-
myocardial infarction (post-MI) patients with left ventricular systolic dys-
function, heart failure, or both, who are not suitable for treatment with
angiotensin-converting enzyme (ACE) inhibitors, compared to placebo.
Methods: A Markov model, using data drawn from the Valsartan in
Acute Myocardial Infarction (VALIANT) trial and other trials, was devel-
oped to predict the future health pathways, resource use, and costs for
patients who have recently experienced an MI. Patients received either
valsartan (mean dose 247 mg) or placebo. Cost data were drawn from
national databases and published literature, although health outcome
utility weights were derived from existing studies. Patient outcomes were
modeled for 10 years, and incremental cost-effective ratios were calculated
for valsartan compared with placebo.
Results: Over a period of 10 years, a cohort of 1000 patients treated with
valsartan experienced 147 fewer cardiovascular deaths, 37 fewer nonfatal
MIs, and 95 fewer cases of heart failure than a cohort who received
placebo. The incremental cost of valsartan, compared with placebo, was
£2680 per patient, although the incremental effectiveness of valsartan was
0.5021 quality-adjusted life-years (QALYs) gained per patient. Therefore,
the incremental cost per QALY for treatment with valsartan was £5338.
When analysis was undertaken using life-years rather than QALYs, the
cost per life-year gained was £4672.
Conclusions: For patients who are not suitable for treatment with ACE
inhibitors, valsartan is a viable and cost-effective treatment for their man-
agement after an MI.
Keywords: cardiovascular disease, economic, heart failure, model, stroke.
Introduction
Myocardial infarction (MI) has severe consequences for both the
patient and the health-care system [1–5]. Valsartan is the only
angiotensin II antagonist licensed for the management of post-MI
patients with left ventricular systolic dysfunction, heart failure,
or both [6]. Although angiotensin-converting enzyme (ACE)
inhibitors are recommended as standard therapy for such
patients, intolerability (e.g., cough) [4] and nonadherence [6,7]
are common problems. Therefore, an alternate is required to
minimize further cardiovascular morbidity and mortality.
The overall objective of this cost-utility study was to estimate
the costs and outcomes associated with treatment with valsartan
for post-MI patients with left ventricular systolic dysfunction
and/or heart failure who are not suitable for treatment with ACE
inhibitors (i.e., those for whom ACE inhibitors had caused intol-
erable adverse events, or for whom adherence was affected by
adverse events). Because these patients are not suitable for treat-
ment with ACE inhibitors, the comparator was placebo (i.e., no
ACE or valsartan treatment).
Methods
A Markov model was constructed using Microsoft Excel 2000
[8]. AMarkov model is a type of quantitative model that involves
a speciﬁc set of mutually exclusive and exhaustive health states
representing the natural course of a disease. Markov models are
a useful approach for estimating the future health pathways,
outcomes, and costs of patients. The model was constructed to
estimate the costs and outcomes after an initial MI for two
cohorts of patients who require medical management and are not
suitable for treatment with ACE inhibitors. Thus, the model
includes one cohort of patients treated with valsartan (mean
dosage of 247 mg  105 mg daily, as in the Valsartan in Acute
Myocardial Infarction (VALIANT) clinical trial [6]) and a second
cohort who received placebo. Patients began treatment between
0 and 10 days after their MI.
The VALIANT trial recently demonstrated the clinical effec-
tiveness and efﬁcacy of valsartan [6] in post-MI patients with
evidence of left-sided heart failure. The VALIANT trial pro-
vided a randomized, double-blinded comparison of valsartan
with captopril (an ACE inhibitor) in more than 14,000 patients
(randomized to three treatment arms) who were followed for
an average of 24.7 months. Other trials have compared ACE
inhibitors against placebo [9–12]. Mortality rates and other
clinical outcomes were estimated for each treatment option
(i.e., valsartan and placebo) using trial data. The trial data were
combined with resource use and unit-cost data to estimate the
relative effects of valsartan and placebo for the treatment of
post-MI patients who are not suitable for treatment with ACE
inhibitors.
The time horizon used for the model was 10 years. This
allowed for any variations in mortality to be captured, as well as
predicting the true long-term costs associated with each treat-
ment. The time horizon was varied in the sensitivity analysis to
see what impact this may have. In the UK, the majority of costs
for post-MI treatment are borne by the National Health Service
(NHS). Therefore, the perspective of the NHS was selected for
this study.
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The Markov Model
The Markov model for this study consisted of ﬁve distinct health
states: 1) no complications (after ﬁrst MI); 2) postheart failure;
3) poststroke; 4) postsubsequent MI and 5) death.
All patients entered the model after their ﬁrst MI (i.e., after
diagnosis and appropriate management of the ﬁrst MI) and
moved to different health states, depending upon the likelihood
of progression (see transition probabilities section). For example,
a patient may have begun with no complications after an initial
MI and may have remained in that state for approximately 2
years. After 2 years, the patient may have suffered a stroke. In
this case, the patient would move to the poststroke state, until a
further change occurred, or until the 10 years were over. Note
that patients who died remain in the death state for the remain-
der of the model. Figure 1 shows the structure of the Markov
model.
For the purposes of this analysis, it was conservatively
assumed that patients who had successive events would maintain
the worst state. For example, a poststroke patient who suffered
heart failure would remain in the poststroke state because the
symptoms after stroke are more severe than those after heart
failure. The list of health states is shown in Table 1.
Cycles in the model lasted for 3 months. Therefore, a patient
who survived for the full 10 years experienced a total of 40
cycles. A 3-month cycle was selected because this allows the
model to incorporate the fact that mortality rates are signiﬁcantly
higher in the ﬁrst 3 months after an MI than in subsequent
months.
Transition Rates and Resource Use
For valsartan, the event rates were drawn from the VALIANT
trial for valsartan patients [6]. For placebo, the rates were drawn
from a meta-analysis [12] of the AIRE [10], SAVE [9], and
TRACE [11] trials for patients treated with placebo. All rates are
shown in Table 2. The VALIANT trial compared the efﬁcacy of
valsartan versus the ACE inhibitor captopril. The AIRE, SAVE,
and TRACE trials compared the efﬁcacy of three different ACE
inhibitors versus placebo after an acute MI (i.e., in a population
similar to that in the VALIANT trial, with recent MI and evi-
dence of impaired left ventricular function). The AIRE, SAVE,
and TRACE trials were synthesized in 2000 [12], and these
overall event rates were used in the model.
Event rates for patients on placebo were calculated as a ratio
of ACE inhibitor rates, as observed in the meta-analysis of the
AIRE, SAVE, and TRACE trials. In line with the VALIANT trial
which showed that valsartan is as effective as captopril [6], it was
assumed that the ratio for valsartan versus placebo was the same
as that of ACE inhibitors against placebo. For example, the
3-month risk of heart failure for placebo patients was 1.33 times
that of ACE inhibitor patients (taken from the meta-analysis of
those trials). Because the risk of admission for heart failure for
valsartan patients in the VALIANT study was 1.3% in the ﬁrst 3
No Complications 
(After First MI) 
Post Heart Failure 
Dead Post Stroke 
Post Subsequent 
MI
Patient enters model
Figure 1 The Markov model. MI, mycardial
infarction.
Table 1 Utility weights for health states
Health state Utility weight SD
No complications after ﬁrst or subsequent MI [13] 0.880 0.05
Poststroke [14] 0.680 0.18
Postheart failure [13] 0.840 0.10*
Death 0.000
Acute events†
Acute MI (disutility) -0.0183
Nonfatal stroke (disutility) -0.0142
Heart failure (disutility) -0.0175
*Assumption.
†For acute events, disutility was calculated by applying a utility of zero for 7 days.The weight
for the remainder of the cycle would be equivalent to the nonacute equivalent.
MI, myocardial infarction.
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months for valsartan patients, it was assumed that the risk for
placebo patients was 1.73% (i.e., 1.33 multiplied by 1.3%). No
patients who were included in the VALIANT trial were excluded
from the economic analysis. Patients receiving valsartan who
experienced adverse events (based on “all discontinuation due
to adverse events” rates observed in the VALIANT trial) were
assumed to discontinue treatment. Thereafter, these patients were
assumed to experience effectiveness equivalent to placebo
therapy.
Because acute events are more likely to occur immediately
after another event, rates were disaggregated into the 3-month
period after an event, and any subsequent 3-month period. Mor-
tality and morbidity rates were calculated using Kaplan–Meier
curves from the VALIANT trial, and probabilities for 3-month
cycles were converted from trial rates (of 24.7 months) using the
formula: P3 months = 1 - (1 - P24.7 months)3/24.7. Due to a lack of avail-
able data, it was not possible to correlate the frequency of events
with the likelihood of further events.
To estimate the costs associated with follow up for stroke,
heart failure, and MI patients, some assumptions based on expert
clinical opinion about resource use were required. For example,
it was assumed that, because of increased dependence and dis-
ability, patients who had experienced a stroke would have three
times the resource use (other than revascularization) of postheart
failure patients. Table 3 shows the annual resource use for these
patients by number of visits per patient or proportion of patients
undergoing procedure.
Health Outcomes
The summary outcome measure used in this study was the
quality-adjusted life-year (QALY). The QALY is a utility mea-
surement quantifying a patient’s health-related quality of life
(morbidity) and length of life (mortality). To calculate total
QALYs, the utility values were multiplied by the duration in each
health state throughout the time horizon of the model. Because
the QALY accounts for both quality and quantity of life, it is
superior to simple effectiveness measures such as event rates
which assign equal weight to all outcomes. For each health state
in the model (i.e., no complications, postheart failure, poststroke,
and death), a utility weight was applied in the range between
0 = dead and 1 = full health.
The utility weights were taken from existing literature
(Table 1). The weights for no complications and heart failure
were drawn from a 1993 study undertaken by Tsevat et al. [13]
who used the time trade-off approach for utility elicitation. The
quality of life associated with poststroke was derived from a
2003 meta-analysis by Tengs and Lin [14] who pooled quality-
of-life data to offer analysts quality-of-life estimates based on
the entire stroke literature rather than just a single estimate.
In addition, it was assumed that, for acute events such as MI,
stroke, and acute heart failure, the patient would experience 7
days of extreme severe impairment to quality of life [15]. There-
fore, it was assumed that patients experienced zero utility for
a 7-day period after an acute event. This assumption was later
tested in the sensitivity analysis.
In addition to QALYs, the total life-years gained for patients
are also reported. Life-years gained are a useful guide to patients’
survival rates but do not account for variation in the quality of
a patient’s life.
Costs
The perspective of the cost-effectiveness analysis was the
cost to the NHS. Because the VALIANT trial was multinational,
resource use and other cost data would not necessarily be reﬂec-
tive of the UK setting. Therefore, in this study, cost and resource
data were drawn from national sources.
The NHS Reference Costs for 2005 were used for inpatient
procedures and outpatient attendances [16]. Average costs were
calculated using the health-related group code for nonfatal MI,
Table 2 Event rates used in the model (transition probabilities)
Event
First 3 months
(%)
Subsequent 3-month
periods (%)
Valsartan*
Cardiovascular death 6.00 1.58
Other death 0.35 0.35
Nonfatal MI 0.73 0.73
Heart failure 1.30 1.28
Nonfatal stroke 0.20 0.20
Discontinue due to adverse events 2.90 0.41
Placebo†
Cardiovascular death 7.77 2.18
Other death 0.35 0.35
Nonfatal MI 0.90 0.90
Heart failure 1.73 1.71
Nonfatal stroke 0.18 0.18
*Source: VALIANT Investigators [6].
†Source: Flather et al. [12], as a ratio of the VALIANT trial results [6].
MI, myocardial infarction.
Table 3 Annual resource use for follow up of patients
Resource Post-MI* Postheart failure Poststroke†
Visits
GP clinic visits 2 2* 6
Cardiologist visits 1 1* 3
Nurse visits 0 13* 39
Investigations
Exercise tolerance test‡ 90% of patients 90% of patients* 90% of patients ¥ 3
Angiography 15% of patients 15% of patients* 15% of patients ¥ 3
Revascularization
PCI§ 9% of patients 9% of patients 9% of patients
CABG 5% of patients 5% of patients 5% of patients
*Source: Expert clinical opinion (Dr. David Newby, Clinician and Senior Lecturer in Cardiology, University of Edinburgh, UK).
†It was assumed that resource use for poststroke patients was three times that of postheart failure patients (see *).
‡It was assumed that 10% of patients would not be suitable for the test (see *).
§Source: [21].
Source: [22].
MI, myocardial infarction; GP, general practitioner; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
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stroke, and heart failure. These costs were weighted to take into
account the proportion of patients who received emergency and
elective care. Table 4 includes the inpatient unit costs used in the
model. Total costs were estimated using the predicted resource
use for each state (from Table 3), multiplied by the unit costs
(Table 4). The unit costs used in the follow-up calculations are
also shown in Table 4. All costs are presented in 2008 prices and
were inﬂated where necessary.
Because health outcomes and costs arising in the future tend
to be valued less than those occurring now, the value of future
outcomes were discounted. Both health outcomes and costs were
discounted at a rate of 3.5% per annum, as recommended by the
National Institute for Health and Clinical Excellence, the Scot-
tish Medicines Consortium, and the Treasury [17,18]. Discount
rates were varied in the sensitivity analysis.
One-way sensitivity analyses were carried out to determine
which parameters had the greatest impact on the model’s ﬁnd-
ings. In most cases, ranges were selected by increasing or decreas-
ing the base case value by 20%.
Results
Incremental Analysis
Table 5 shows the incremental results. Over a period of 10 years,
the valsartan cohort experienced 431 cardiovascular deaths
per 1000 patients compared with 578 in the placebo group. The
valsartan group experienced 178 nonfatal MIs, 314 cases of
heart failure, and 48 strokes over 10 years compared with 215,
409 and 43, respectively, in the placebo group.
In the base case analysis, the valsartan cohort cost an average
of £8878 per patient over the 10-year period. In comparison, the
placebo cohort cost an average of £6198 per patient over the
same period (these costs reﬂect treatment for adverse events and
other follow-up costs). Therefore, the incremental cost of valsar-
tan was £2680 per patient. Patients in the valsartan group expe-
rienced a total of 5.021 QALYs per patient, compared with 4.519
QALYs in the placebo group. Therefore, 0.502 additional
QALYs were gained over the 10 years modeled.
The incremental cost per QALY gained for treatment with
valsartan was, therefore, £5338. When the analysis was under-
taken using life-years rather than QALYs, the cost per life-year
gained was £4672.
One-Way Sensitivity Analysis
Table 6 shows the relative effects of various changes to key
parameters used in the Markov model.
The utility weight applied to having no complications had a
major impact on the model’s ﬁndings. When the utility weight
was increased to 1.00, the cost per QALY gained fell to £4726.
This is due to the increased beneﬁts associated with valsartan
which reduces the risk of complications. When the utility weight
was decreased by 20% (to 0.70), the incremental cost-effective
ratio (ICER) increased to £6624. The event rates for cardiovas-
cular death were also key drivers in the model.
The model was robust to many factors, including the cost of
events, the cost of follow-ups, the quality of life associated with
poststroke and postheart failure, and changes in the likelihood of
patients discontinuing valsartan.
Probabilistic Sensitivity Analysis
Probabilistic sensitivity analysis (PSA) was undertaken to esti-
mate the level of conﬁdence around the model’s cost-effectiveness
outputs. Distributions were ﬁtted to key model parameters where
data were available (see Tables 1 and 4). The outputs from the
PSA show relatively little variation in the incremental costs and
outcomes (see Fig. 2). As such, the cost-effectiveness acceptability
curve (Fig. 3) shows that there is a high degree of conﬁdence
associated with valsartan being a cost-effective intervention.
Discussion
The cost-effectiveness estimate of valsartan after an MI in
patients with evidence of left ventricular systolic dysfunction,
heart failure, or both, who are unsuitable for ACE inhibitors
compared to placebo with a 10-year time horizon was £5338 per
QALY. No other studies have undertaken a cost-effective analysis
of treatments speciﬁcally for post-MI patients who are not suit-
able for treatment with ACE inhibitors. Several studies, however,
have assessed the cost-effectiveness of ACE inhibitors, including
Tsevat et al., who showed that the cost-effectiveness of captopril
(compared with placebo) after MI ranged between US$3600 and
US$60,800 per QALY (US dollar, 1991 prices), depending on the
age of the patient and the persistence of treatment beneﬁts [19].
Martinez and Ball estimated that the cost-effectiveness of rami-
pril (compared with placebo) was around £300 per life-year
gained (1993 prices) [20].
Table 4 Unit costs used in the model
Resource Cost (2008 £) SD
Single events*
Cardiovascular death† 1317.21 1000‡
Nonfatal MI 1176.57 1167
Stroke 2275.47 1677
Heart failure 1535.521 734
Other death§ 375.75 200‡
Follow-up costs
GP visit 20.99
Cardiologist visit 71.37
Nurse visit 18.89
Investigations
Exercise tolerance test¶ 28.34
Angiography* 390.44
Revascularization*
PCI 3015.42
CABG 7492.88
Drug costs#
Valsartan (3 months of treatment) 108.97
*Source: NHS Reference Costs [16] unless stated otherwise.
†Source: Grover et al. [23], reﬂated to 2008 prices.
‡Assumption.
§Cost of other death included one ambulance journey and a 50% to 50% mix ofA&E visit and
GP home visit, respectively.
Source: Curtis and Netten [24].
¶Calculated by multiplying the cost of a nurse visit by 1.5 (representing nurse time,plus other,
i.e., equipment and analysis of results).
#Source: British National Formulary 55 [25], mean dosage 247 mg daily.
MI, myocardial infarction; GP, general practitioner; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft.
Table 5 Incremental results
Valsartan Placebo Incremental
Cost £8878 £6198 £2680
QALYs 5.021 4.519 0.502
LYs 5.803 5.230 0.574
Incremental cost per QALY £5338
Incremental cost per LY £4672
QALY, quality-adjusted life-year; LY, life-year.
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This economic evaluation used effectiveness data drawn
directly from the VALIANT trial and disaggregated outcomes
into ﬁve events (no complications, stroke, heart failure, subse-
quent MI, and death). The proportion of patients in each state
during the 10-year period can be estimated from the model. In
the placebo group of the model, the survival rate for patients
after 10 years was 33.83% compared with 42.85% in the val-
sartan group. The difference in mortality was apparent from the
outset, with 85.09% of placebo patients surviving the ﬁrst year
compared with 88.28% of valsartan patients. This was a key
factor in the cost-effectiveness results, suggesting that both
quality and quantity of life are improved by treatment with
valsartan.
The VALIANT trial was undertaken on 14,703 patients from
24 different countries. There is no evidence that individual cases
of MI in the UK are more severe than in other countries. There-
fore, it is reasonable to assume that these ﬁndings are applicable
to UK patients. Although effectiveness data from several coun-
tries were used, the economic model was populated with UK cost
and resource use data.
This analysis is not without its limitations. Data were
obtained from the published literature and therefore, some
assumptions were required. For example, on the one hand, effec-
tiveness data for valsartan were drawn from the VALIANT trial
[6], which undertook analysis on patients receiving valsartan,
captopril, or both, and which excluded patients unsuitable for
treatment with ACE inhibitors. On the other hand, this cost-
effectiveness analysis focused on patients who were unsuitable
for treatment with ACE inhibitors. Therefore, it was necessary to
assume that patients who are not suitable for ACE inhibitors
Table 6 Sensitivity-analysis results
Variable (base value) Low parameter value ICER (£) High parameter value ICER (£)
Base case scenario ICER £5,338
Costs
Cardiovascular death (£1317) £659 5,459 £1,976 5,217
Nonfatal MI (£1177) £588 5,357 £1,765 5,319
Stroke (£2275) £1,138 5,321 £3,413 5,355
Heart failure (£1536) £768 5,419 £2,303 5,256
Other death (£376) £188 5,335 £564 5,341
Post-MI follow up (£844) £422 4,793 £1,266 5,882
Post-stroke follow up (£1935) £967 5,269 £2,902 5,407
Postheart failure follow up (£1076) £537 5,428 £1,614 5,248
Cost of valsartan (£109 per cycle) £54 2,990 £163 7,685
QALY
No complications (and post-MI) (0.88) 0.70 6,624 1 4,726
Post nonfatal stroke (0.68) 0.54 5,394 0.82 5,283
Postheart failure (0.84) 0.67 5,167 1 5,504
Event rates* (First 3 months, later 3 months)
Valsartan
Cardiovascular death (6.00%, 1.58%) 4.8%, 1.26% 3,867 7.2%, 1.9% 10,426
Nonfatal MI (0.73%, 0.73%) 0.37%, 0.37% 5,354 1.48%, 1.48% 5,305
Heart failure (1.3%, 1.28%) 0.59%, 0.59% 5,448 2.60%, 2.60% 5,187
Nonfatal stroke (0.20%, 0.20%) 0.10%, 0.10% 5,248 0.40%, 0.40% 5,528
Discontinue due to adverse events (2.90 %, 0.41%) 1.45%, 0.20% 5,309 5.80%, 0.82% 5,397
Other
Discount rate† (3.5%) 0% 5,127 6% 5,494
*Both ﬁrst 3-month and subsequent 3-month periods were increased/decreased by 20%.
†Both costs and beneﬁts were discounted at the same rates.
ICER, incrementl cost-effective ratio; MI, myocardial infarction.
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Figure 2 Cost-effectiveness scatter plot. QALYs,
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would experience similar beneﬁts of valsartan because patients
who are suitable for ACE inhibitors. Expert opinion was used for
some model inputs where published data were not available.
Nevertheless, such use was based on alternate data (e.g., a similar
condition) and was tested in the sensitivity analysis.
The treatment effects were assumed to last for the duration of
the model. Nevertheless, it was also assumed that treatment (and,
therefore, treatment cost) would continue throughout the model.
If the effectiveness of treatment were to discontinue, then the
patient could be assumed to stop treatment. As such, the incre-
mental effectiveness and cost would be reduced by an equal
proportion because patients would switch to a treatment equiva-
lent to that of the comparator group.
Other costs, such as nursing homes, were excluded from the
analysis because of a lack of reliable resource use data. This
assumption is likely to be conservative because improved health
outcomes would be more likely to be associated with reduced
resource utilization.
Conclusions
The estimated ICER for valsartan in this study is well within the
bounds of cost-effectiveness acceptability implied by decision-
making bodies. Furthermore, sensitivity analysis demonstrated
that changes to key parameters did not increase the ICER
signiﬁcantly close to such thresholds. Therefore, for patients
with evidence of with left ventricular systolic dysfunction, heart
failure, or both, who are not suitable for treatment with ACE
inhibitors, valsartan is a viable and cost-effective treatment for
their management after MI.
Source of ﬁnancial support: Novartis Pharmaceuticals for health econom-
ics consultancy in the development of this study.
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